How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation
H Einsele, P Ljungman… - Blood, The Journal of the …, 2020 - ashpublications.org
Cytomegalovirus (CMV) reactivation remains one of the most common and life-threatening
infectious complications following allogeneic hematopoietic stem cell transplantation …
infectious complications following allogeneic hematopoietic stem cell transplantation …
Cytomegalovirus retinitis in HIV and non-HIV individuals
M Munro, T Yadavalli, C Fonteh, S Arfeen… - Microorganisms, 2019 - mdpi.com
Cytomegalovirus retinitis (CMVR) is a severe, vision-threatening disease that primarily
affects immunosuppressed patients. CMVR is the most common ocular opportunistic …
affects immunosuppressed patients. CMVR is the most common ocular opportunistic …
[HTML][HTML] American Society for Transplantation and Cellular Therapy Series:# 4-Cytomegalovirus treatment and management of resistant or refractory infections after …
MK Yong, TL Shigle, YJ Kim, PA Carpenter… - … and Cellular Therapy, 2021 - Elsevier
Abstract The Practice Guidelines Committee of the American Society of Transplantation and
Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID …
Cellular Therapy (ASTCT) partnered with its Transpl. Infect. Dis. Special Interest Group (TID …
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors “leflunomide” and “teriflunomide” in Covid-19: A narrative review
Dihydroorotate dehydrogenase (DHODH) is rate-limiting enzyme in biosynthesis of
pyrimidone which catalyzes the oxidation of dihydro-orotate to orotate. Orotate is utilized in …
pyrimidone which catalyzes the oxidation of dihydro-orotate to orotate. Orotate is utilized in …
Anti-CMV therapy, what next? A systematic review
C Gourin, S Alain, S Hantz - Frontiers in Microbiology, 2023 - frontiersin.org
Human cytomegalovirus (HCMV) is one of the main causes of serious complications in
immunocompromised patients and after congenital infection. There are currently drugs …
immunocompromised patients and after congenital infection. There are currently drugs …
An update on current antiviral strategies to combat human cytomegalovirus infection
K Panda, D Parashar, R Viswanathan - Viruses, 2023 - mdpi.com
Human cytomegalovirus (HCMV) remains an essential global concern due to its distinct life
cycle, mutations and latency. As HCMV is a herpesvirus, it establishes a lifelong persistence …
cycle, mutations and latency. As HCMV is a herpesvirus, it establishes a lifelong persistence …
An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection
Z Pan, Z Wan, Y Wang, S Zha, J Zhang, H Chen… - Frontiers in …, 2023 - frontiersin.org
Objective To evaluate the efficacy and safety of leflunomide for the treatment of acute,
symptomatic COVID-19. Methods A single-center, open-label, randomized controlled trial …
symptomatic COVID-19. Methods A single-center, open-label, randomized controlled trial …
[HTML][HTML] ML390 inhibits enterovirus 71 replication by targeting de novo pyrimidine biosynthesis pathway
Q Yang, C Wu, G Zhu, F Ren, B Lin, R Huang, X Hu… - Antiviral Research, 2023 - Elsevier
Abstract Enterovirus 71 (EV71), a small, single-stranded, positive-sense RNA virus
belonging to the enterovirus genus in the family Picornaviridae, causes hand, foot, and …
belonging to the enterovirus genus in the family Picornaviridae, causes hand, foot, and …
Cell therapy for cytomegalovirus infection
L Neill, K Peggs - Expert Opinion on Biological Therapy, 2021 - Taylor & Francis
Introduction Cytomegalovirus (CMV) infection is widely prevalent but mostly harmless in
immunocompetent individuals. In the post hematopoietic stem cell transplant (HSCT) setting …
immunocompetent individuals. In the post hematopoietic stem cell transplant (HSCT) setting …
Prediction of cytomegalovirus reactivation by recipient cytomegalovirus-IgG titer before allogeneic hematopoietic stem cell transplantation
S Kawamura, H Nakasone, J Takeshita… - … and Cellular Therapy, 2021 - Elsevier
Recipient cytomegalovirus (CMV) seropositivity is known to be a risk factor for CMV
reactivation after allogeneic hematopoietic stem cell transplantation (allo-HCT). We explored …
reactivation after allogeneic hematopoietic stem cell transplantation (allo-HCT). We explored …